Sharh maqola

Immunotherapy of targeting MDSCs in tumor microenvironment

Hongshu SuiDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaShengyi DongyeDepartment of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, ChinaXiaocui LiuDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaXinghua XuDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaLi WangDepartment of Pathology and Forensic Medicine, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaChristopher Q. JinDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY, United StatesMinhua YaoDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaZhaoqing GongDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaDaniel JiangDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY, United StatesKexin ZhangDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY, United StatesYaling LiuDepartment of Pathology, The Second Affiliated Hospital of Shandong First Medical University, Taian, Shandong, ChinaHui LiuDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, ChinaGuomin JiangDepartment of Medicine, School of Medicine, University of Louisville, Louisville, KY, United StatesYanping SuDepartment of Histology and Embryolog, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China

2022en

ABI

Annotatsiya

Myeloid-derived suppressor cells (MDSCs) are a group of heterogeneous cells which are abnormally accumulated during the differentiation of myeloid cells. Immunosuppression is the main functional feature of MDSCs, which inhibit T cell activity in the tumor microenvironment (TME) and promote tumoral immune escape. The main principle for immunotherapy is to modulate, restore, and remodel the plasticity and potential of immune system to have an effective anti-tumor response. In the TME, MDSCs are major obstacles to cancer immunotherapy through reducing the anti-tumor efficacy and making tumor cells more resistant to immunotherapy. Therefore, targeting MDSCs treatment becomes the priority of relevant studies and provides new immunotherapeutic strategy for cancer treatment. In this review, we mainly discuss the functions and mechanisms of MDSCs as well as their functional changes in the TME. Further, we review therapeutic effects of immunotherapy against MDSCs and potential breakthroughs regarding immunotherapy targeting MDSCs and immune checkpoint blockade (ICB) immunotherapy.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3389/fimmu.2022.990463

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar